lyophilized powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-15. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
=== Augmentation === Physicians often add a medication with a different mode of action to bolster the effect of an antidepressant in cases of treatment resistance; a 2002 large community study of 244,859 depressed Veterans Administration patients found that 22% had received a second agent, most commonly a second antidepressant. Stephen M. Stahl, renowned academician in psychopharmacology, has stated resorting to a dynamic psychostimulant, in particular, d-amphetamine is the "classical augmentation strategy for treatment-refractory depression". However, the use of stimulants in cases of treatment-resistant depression is relatively controversial. It is also possible to use a benzodiazepine as to improve sleep without impairing the antidepressant response specially in patients presenting symptoms of insomnia and disturbed sleep. A randomized controlled trial found that the use of eszopiclone with fluoxetine resulted in a better remission rate. Addition of atypical antipsychotics when the patient has not responded to an antidepressant is also known to increase the effectiveness of antidepressant drugs, albeit at the cost of more frequent and potentially serious side effects.
In the Soviet Union, a Union Republic (Russian: Сою́зная Респу́блика, romanized: Soyúznaya Respúblika) or unofficially a Republic of the USSR was a constituent federated political entity with a system of government called a Soviet republic, which was officially defined in the 1977 constitution as "a sovereign Soviet socialist state which has united with the other Soviet republics to form the Union of Soviet Socialist Republics" and whose sovereignty is limited by membership in the Union. As a result of its status as a sovereign state, the Union Republic de jure had the right to enter into relations with foreign states, conclude treaties with them and exchange diplomatic and consular representatives and participate in the activities of international organizations (including membership in international organizations). The Union Republics were perceived as national-based administrative units of the Union of Soviet Socialist Republics (USSR). The Soviet Union was formed in 1922 by a treaty between the Soviet republics of Byelorussia, Russian SFSR (RSFSR), Transcaucasian Federation, and Ukraine, by which they became its constituent republics of the Union of Soviet Socialist Republics (Soviet Union). For most of its history, the USSR was a one-party state led by the Communist Party of the Soviet Union.
== Cause == G6PD deficiency results from mutations in the G6PD gene. The G6PD gene contributes to the production of glucose-6-phosphate dehydrogenase. Chemical reactions involving glucose-6-phosphate dehydrogenase produce compounds that prevent reactive oxygen species from building up to toxic levels within red blood cells. If a reduction in the amount of glucose-6-phosphate dehydrogenase or alteration of structure occurs due to G6PD gene mutations, the enzyme loses its protective role, leading to the accumulation of reactive oxygen species and thus damaging red blood cells.
Sources: en.wikipedia.org
Once again the Universe gives the appearance of being biologically constructed, and on this occasion on a truly vast scale. Once again those who consider such thoughts to be too outlandish to be taken seriously will continue to do so. While we ourselves shall continue to take the view that those who believe they can match the complexities of the Universe by simple experiments in their laboratories will continue to be disappointed. Wickramasinghe attempts to present scientific evidence to support the notion of cosmic ancestry and "the possibility of high intelligence in the Universe and of many increasing levels of intelligence converging toward a God as an ideal limit." During the 1981 scientific creationist trial in Arkansas, Wickramasinghe was the only scientist testifying for the defense, which in turn was supporting creationism. In addition, he wrote that the Archaeopteryx fossil finding is a forgery, a charge that the scientific community considers an "absurd" and "ignorant" statement.
The trust's executive directors discussed involving the police but instead commissioned a review by the Royal College of Paediatrics and Child Health (RCPCH). Letby was taken off the unit on 30 June, and the hospital subsequently reduced cot capacity and raised the gestational‑age threshold for admissions. The RCPCH review began in September 2016. Its October report found no definitive explanation for the increased mortality rate but identified inadequate staffing and senior cover. It described concerns about Letby as subjective and unsupported by evidence. The trust's medical director asked consultant neonatologist Jane Hawdon to undertake detailed case reviews recommended by the RCPCH. Hawdon instead conducted a review of medical notes relating to 17 deaths and collapses; she was understood to have told the hospital's medical director that she had not been able to conduct the thorough review that the RCPCH had recommended due to not having had the time, and later said that she had not been "adequately briefed" about the concerns about Letby before she carried out her analysis. The report concluded that most of the deaths and collapses could be explained and might have been preventable with different care, while four warranted further local forensic review. Minutes of a subsequent board meeting recorded the medical director stating that the RCPCH and Hawdon reviews attributed the deaths to leadership and intervention issues; the board chair later said he had been misled about the depth of Hawdon's review.
=== Contraindications === The use of lysine vasopressin is contraindicated in the presence of hypersensitivity to beef or pork proteins, increased BUN and chronic kidney failure. It is recommended that it be cautiously used in instances of perioperative polyuria, sensitivity to the drug, asthma, seizures, heart failure, a comatose state, migraine headaches, and cardiovascular disease.
=== Pulmonary hypertension === While sildenafil improves some markers of disease in people with pulmonary arterial hypertension, it does not appear to affect the risk of death or serious side effects.
Sources: en.wikipedia.org
== Safety considerations == Sodium azide can be fatally toxic, and even minute amounts can cause symptoms. The toxicity of this compound is comparable to that of soluble alkali cyanides, although no toxicity has been reported from spent airbags. It produces extrapyramidal symptoms with necrosis of the cerebral cortex, cerebellum, and basal ganglia. Toxicity may also include hypotension, blindness and hepatic necrosis. Sodium azide increases cyclic GMP levels in the brain and liver by activation of guanylate cyclase. Sodium azide solutions react with metallic ions to precipitate metal azides, which can be shock sensitive and explosive. This should be considered for choosing a non-metallic transport container for sodium azide solutions in the laboratory. This can also create potentially dangerous situations if azide solutions should be directly disposed down the drain into a sanitary sewer system. Metal in the plumbing system could react, forming highly sensitive metal azide crystals which could accumulate over years. Adequate precautions are necessary for the safe and environmentally responsible disposal of azide solution residues.
In December 2017 the company announced that in the summer of 2018 Geoffrey Babidge, who had been nearing retirement age, would step down and Jayne Hrdlicka would take over as CEO; at that time she was CEO of a subsidiary of Qantas. She took over in July 2018. At that time the company was experiencing strong growth via sales in China and had ramped up spending to further increase Chinese sales and to expand the US market. Hrdlicka resigned as CEO in December 2019, after her husband was found to have a kidney tumour. On her departure Geoffrey Babidge returned, as interim CEO. In August 2020 David Bortolussi was appointed CEO and managing director.
Public awareness and advocacy play crucial roles in driving the research agenda and policy development for CEC, highlighting the need for updated manufacturing practices and developing more remediation and detection methods.
Transthoracic echocardiography is not recommended in the evaluation of aortic dissections owing to its limited ability to evaluate the aortic arch, the descending aorta or the blood vessels branching from the aorta. Its sensitivity may be further reduced in patients with obesity or lung emphysema. Transthoracic echocardiography has high sensitivity in evaluating the aortic root and proximal ascending aorta. It can also be done at bedside and no sedation is required. It may also identify complications of aortic dissection including heart failure, pericardial effusion with possible cardiac tamponade, and aortic valve regurgitation or other valve disorders. Transesophageal echocardiography has a sensitivity of 96.8% and specificity of 100% in the diagnosis of aortic dissections. It is also able to assess the descending aorta in the thorax. It can also assess the aortic valve and other heart valves, as well as assess the true lumen or false lumin of aortic dissections, which can help guide surgical repair planning and options. Transesophageal echocardiography requires the person to be sedated.
The recent patent literature describes the synthesis of glycocyamine by catalytic oxidation of ethanolamine to glycine and subsequent reaction with cyanamide in aqueous solution in high yield, analogous to the synthesis of creatine starting from 2-methylaminoethanol via sarcosine.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.